GSTC (GlobeStar Therapeutics) Current Accrued Expense: $0.22 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlobeStar Therapeutics Current Accrued Expense?

GlobeStar Therapeutics GSTC -99.00% Current Accrued Expense is $0.22 Mil as of Jun. 2024.

GlobeStar Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2024 was $0.22 Mil.

GlobeStar Therapeutics's quarterly Current Accrued Expense declined from Dec. 2023 ($0.23 Mil) to Mar. 2024 ($0.22 Mil) and declined from Mar. 2024 ($0.22 Mil) to Jun. 2024 ($0.22 Mil).

GlobeStar Therapeutics's annual Current Accrued Expense increased from Sep. 2021 ($0.22 Mil) to Sep. 2022 ($0.23 Mil) but then stayed the same from Sep. 2022 ($0.23 Mil) to Sep. 2023 ($0.23 Mil).

GlobeStar Therapeutics Current Accrued Expense Related Terms

GlobeStar Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for GlobeStar Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlobeStar Therapeutics Current Accrued Expense Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.23 0.22 0.23 0.23

GlobeStar Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.23 0.23 0.22 0.22

GlobeStar Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.22 Mil mean?
GlobeStar Therapeutics (GSTC) has a Current Accrued Expense of $0.22 Mil as of Jun. 2024. Current Accrued Expense records the total amount of accrued expenses. View historical data on GlobeStar Therapeutics and its competitors.
Is GlobeStar Therapeutics' Current Accrued Expense too high?
GlobeStar Therapeutics' current Current Accrued Expense is $0.22 Mil.
How does GlobeStar Therapeutics' Current Accrued Expense compare to GBLX and ENDV?
GlobeStar Therapeutics' Current Accrued Expense of $0.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on GlobeStar Therapeutics and its competitors. GlobeStar Therapeutics's current Current Accrued Expense is $0.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlobeStar Therapeutics stock overvalued right now?
GlobeStar Therapeutics (GSTC) has a current Current Accrued Expense of $0.22 Mil. The current Current Accrued Expense is $0.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For GlobeStar Therapeutics (GSTC), the current Current Accrued Expense is $0.22 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlobeStar Therapeutics Business Description

Address 719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.